Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1619-7089
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review ; day:6 ; month:3 ; year:2021 ; pages:1-14
European journal of nuclear medicine and molecular imaging ; (6.3.2021), 1-14

Urheber
Manafi-Farid, Reyhaneh
Harsini, Sara
Saidi, Bahare
Ahmadzadehfar, Hojat
Herrmann, Ken
Briganti, Alberto
Walz, Jochen
Beheshti, Mohsen
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00259-021-05237-y
URN
urn:nbn:de:101:1-2021041920152446108677
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:57 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Manafi-Farid, Reyhaneh
  • Harsini, Sara
  • Saidi, Bahare
  • Ahmadzadehfar, Hojat
  • Herrmann, Ken
  • Briganti, Alberto
  • Walz, Jochen
  • Beheshti, Mohsen
  • SpringerLink (Online service)

Ähnliche Objekte (12)

2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Assoziation zwischen molekularpathologischen Alterationen beim papillären Schilddrüsenkarzinom und dem Auftreten einer radiojodrefraktären Erkrankung

Assoziation zwischen molekularpathologischen Alterationen beim papillären Schilddrüsenkarzinom und dem Auftreten einer radiojodrefraktären Erkrankung

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy

Evaluation of thresholding methods for the quantification of [68Ga]Ga-PSMA-11 PET molecular tumor volume and their effect on survival prediction in patients with advanced prostate cancer undergoing [177Lu]Lu-PSMA-617 radioligand therapy

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?

The novel PROMISE framework for PSMA-PET reporting: ready for the clinical routine?

Early PSA change after [177Lu]PSMA-617 radioligand therapy as a predicator of biochemical response and overall survival

Early PSA change after [177Lu]PSMA-617 radioligand therapy as a predicator of biochemical response and overall survival

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

Affordable and personalized solutions for radiation therapy of superficial skin tumors : [kumulative Dissertation]

Affordable and personalized solutions for radiation therapy of superficial skin tumors : [kumulative Dissertation]

Verbundene Objekte